<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065386</url>
  </required_header>
  <id_info>
    <org_study_id>2019/91</org_study_id>
    <nct_id>NCT04065386</nct_id>
  </id_info>
  <brief_title>Transcutaneous Auricular Vagal Nerve Stimulation for Post-coma Patients With Disorders of Consciousness</brief_title>
  <official_title>Transcutaneous Auricular Vagal Nerve Stimulation for Post-coma Patients With Disorders of Consciousness: a Randomized Double-blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-invasive brain stimulations techniques have recently shown promising results in patients&#xD;
      with disorders of consciousness. Notably, a case reported improvement of level of&#xD;
      consciousness using transcutaneous auricular vagal nerve stimulation in a patient in&#xD;
      unresponsive wakefulness syndrome.&#xD;
&#xD;
      Here we aim to assess the effects of transcutaneous auricular vagal nerve stimulation on&#xD;
      post-coma patients with disorders of consciousness in a first randomized controlled trial. To&#xD;
      measure these effects, behavioral (Coma recovery scale revised - CRS-R -primary outcome, and&#xD;
      pupillary diameter - secondary outcomes) and neuro-electrophysiological (i.e.,&#xD;
      electroencephalography - EEG - secondary outcome and electrocardiography - EKG - secondary&#xD;
      outcome) will be recorded in severely brain-injured patients with DOC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, therapeutic options for severely brain-injured patients with disorders of&#xD;
      consciousness (DOC), including patients in unresponsive wakefulness syndrome (UWS) and&#xD;
      minimally conscious state (MCS), are limited and still need to be improved to influence&#xD;
      long-term outcomes. Non-invasive brain stimulations (NIBS) techniques have recently shown&#xD;
      promising results in DOC.&#xD;
&#xD;
      Transcutaneous auricular vagal nerve stimulation (taVNS-R, tVNS Technologies GmbH, Germany)&#xD;
      seems to be a promising approach. In a recent case report, a patient in UWS improved to MCS&#xD;
      using this therapeutic technique.&#xD;
&#xD;
      To confirm this positive result, we propose a first randomized double-blind controlled trial.&#xD;
      The patients will be randomized in the active stimulation group and will receive the&#xD;
      stimulation at the cymba conchae or in the sham stimulation group and will receive the&#xD;
      stimulation at the ear lobe. All stimulations will be performed for 45 minutes bilaterally&#xD;
      between 7 and 28 days post-injury in severely brain-damaged patients with disorders of&#xD;
      consciousness. The stimulation will start at 3 mA and will be decreased if signs of pain were&#xD;
      observed (more than 4/9 according to the Nociceptive Coma Scale-Revised - NCS-R) until&#xD;
      stimulation stays under pain threshold.&#xD;
&#xD;
      Behavioral assessments will be performed using the Coma Recovery Scale-Revised before and&#xD;
      after each session by an investigator blinded to the treatment allocation. Then, ten to&#xD;
      fifteen minutes of high-density EEG will be recorded using a 128/256-channel saline electrode&#xD;
      net (Electrical Geodesics, USA) directly before and will continue until ten to fifteen&#xD;
      minutes after each session. During this same period of time, electrocardiography (EKG) and&#xD;
      pupillary measurement (Eye tracking, Phasya, Belgium or Eye Link II, Sr-Research, Canada)&#xD;
      will be recorded to measure parasympathetic indirect signs of vagal stimulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CRS-R total score</measure>
    <time_frame>Before the installation of the EEG equipment in the pre-stimulation period and 5 minutes after the post-stimulation resting EEG (immediately after removing the equipment).</time_frame>
    <description>Behavioral improvement measured by standardized scale. This scale is ranging from 0 to 23, highest score represents more signs of consciousness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in EEG</measure>
    <time_frame>Continuously from 15 min before to 15 min after the stimulation period.</time_frame>
    <description>Improvement in cerebral activity i.e. power spectrum in the alpha band and connectivity measured by EEG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pupil diameter</measure>
    <time_frame>Continuously from 15 min before to 15 min after the stimulation period.</time_frame>
    <description>Through glasses, constant measure of the pupil diameter, indirect sign of parasympathetic stimulation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Consciousness Disorder</condition>
  <condition>Minimally Conscious State</condition>
  <condition>Vegetative State</condition>
  <arm_group>
    <arm_group_label>Active taVNS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) bilaterally, at the cymba conchae, the active localization.&#xD;
It will be preceded and followed by a clinical assessment (Coma Recovery Scale- Revised) and simultaneously to a neurophysiological assessment (128/256 channels EEG, electrocardiograph and pupillary measure).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham taVNS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) bilaterally, at the ear lobe, the sham localization.&#xD;
It will be preceded and followed by a clinical assessment (Coma Recovery Scale- Revised) and simultaneously to a neurophysiological assessment (128/256 channels EEG, electrocardiograph and pupillary measure).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active taVNS</intervention_name>
    <description>Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS), at the cymba conchae, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.</description>
    <arm_group_label>Active taVNS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham taVNS</intervention_name>
    <description>Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS), at the ear lobe, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.</description>
    <arm_group_label>Sham taVNS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  State of consciousness: unresponsive wakefulness syndrome (UWS) and minimally&#xD;
             conscious state (MCS) as defined by CRS-R performed during the screening period.&#xD;
&#xD;
          -  Cerebral damage of known etiology&#xD;
&#xD;
          -  Time since injury between 7 and 28 days&#xD;
&#xD;
          -  No previous history of neurological disorders&#xD;
&#xD;
          -  Intact skin at the ears&#xD;
&#xD;
          -  Consent given by the substitute decision maker&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anyone who is deemed medically unsuitable for this study as determined by a physician&#xD;
             involved with the study&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Cerebral shunt&#xD;
&#xD;
          -  Craniectomy&#xD;
&#xD;
          -  Active implant (i.e. pacemaker)&#xD;
&#xD;
          -  History of heart infarct or arrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurore Thibaut, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Liège</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Michèle Briand, MD, MSc</last_name>
    <phone>+32 4 284 31 13</phone>
    <email>mm.briand@doct.uliege.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurore Thibaut, PhD</last_name>
    <phone>+32 4 284 31 13</phone>
    <email>aurore.thibaut@uliege.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Michele Briand, MD, MSc</last_name>
      <phone>+32 4 284 31 13</phone>
      <email>mm.briand@doct.uliege.be</email>
    </contact>
    <contact_backup>
      <last_name>Aurore Thibaut, PhD</last_name>
      <phone>+32 4 284 31 13</phone>
      <email>aurore.thibaut@uliege.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Michele Briand, MD</last_name>
      <phone>+32 4 284 31 13</phone>
      <email>mm.briand@doct.uliege.be</email>
    </contact>
    <contact_backup>
      <last_name>Aurore Thibaut, PhD</last_name>
      <phone>+32 4 284 31 13</phone>
      <email>aurore.thibaut@uliege.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Western University</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Michele Briand, MD</last_name>
      <phone>+1 581-980-3570</phone>
      <email>mbriand4@uwo.ca</email>
    </contact>
    <contact_backup>
      <last_name>Dawn D Pavich</last_name>
      <phone>+1 519-661-2111</phone>
      <phone_ext>84672</phone_ext>
      <email>dpavich@uwo.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Adrian Owen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Yu YT, Yang Y, Wang LB, Fang JL, Chen YY, He JH, Rong PJ. Transcutaneous auricular vagus nerve stimulation in disorders of consciousness monitored by fMRI: The first case report. Brain Stimul. 2017 Mar - Apr;10(2):328-330. doi: 10.1016/j.brs.2016.12.004. Epub 2016 Dec 14.</citation>
    <PMID>28017322</PMID>
  </reference>
  <reference>
    <citation>Yakunina N, Kim SS, Nam EC. Optimization of Transcutaneous Vagus Nerve Stimulation Using Functional MRI. Neuromodulation. 2017 Apr;20(3):290-300. doi: 10.1111/ner.12541. Epub 2016 Nov 29.</citation>
    <PMID>27898202</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 21, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Aurore Thibaut</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Vagus nerve stimulation</keyword>
  <keyword>Transcutaneous electrical nerve stimulation</keyword>
  <keyword>Non-invasive brain stimulation</keyword>
  <keyword>Neuromodulation</keyword>
  <keyword>High-density EEG</keyword>
  <keyword>Unresponsive wakefulness syndrome</keyword>
  <keyword>Vegetative state</keyword>
  <keyword>Minimally Conscious state</keyword>
  <keyword>Consciousness disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Consciousness Disorders</mesh_term>
    <mesh_term>Persistent Vegetative State</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

